SELLAS Life Sciences Group, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
SELLAS reported Q2 2026 net loss of $9.6M (vs. $6.6M in Q2 2025) on R&D expenses of $6.3M (vs. $3.9M prior year). Cash position strong at $138.3M as of June 30, 2026 (vs. $71.8M at year-end 2025). Key milestones: Phase 3 REGAL trial of GPS approaching pre-specified 80th event triggering final efficacy analysis; Phase 2 SLS009 in AML has enrolled 28 of 80 patients with topline data expected Q4 2026; preclinical data showing SLS009 efficacy in pancreatic cancer.
Why this rating
Clinical progress on two programs supports pipeline but no transformational news. Strong cash ($138M = 63% of market cap) extends runway. Increased burn rate and dilution (share count up 32% year-to-date) offset by advancement toward GPS BLA-triggering event.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.